# A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation

> **NCT00504556** · PHASE2 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 1146 (actual)

## Conditions studied

- Atrial Fibrillation
- Thromboembolism

## Interventions

- **DRUG:** Edoxaban (DU-176b)
- **DRUG:** Edoxaban (DU-176b)
- **DRUG:** Edoxaban (DU-176b)
- **DRUG:** Edoxaban (DU-176b)
- **DRUG:** warfarin

## Key facts

- **NCT ID:** NCT00504556
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 1146 (ACTUAL)
- **Last updated:** 2019-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00504556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00504556, "A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00504556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*